海马保护预防性颅脑照射治疗局限期小细胞肺癌的前瞻性研究
该前瞻性研究纳入20例对放化疗达完全缓解且无脑转移的局限期小细胞肺癌成人患者,给予海马保护PCI 25 Gy/10次,海马平均剂量<8 Gy。2年总生存率88%,认知测试无显著下降,但无症状脑转移累积发生率20%,2例失败位于低剂量区。
要点
- 海马保护PCI 25 Gy/10次后6和12个月认知测试无显著下降
- 2年总生存率88%,无症状脑转移累积发生率20%
- 2例低剂量区失败,均非齿状回,1例累及保护区域
核心结论
- 海马保护可能减轻全脑放疗的神经心理后遗症,但存在保护区域失败风险。
- 数据支持继续入组正在进行的协作组随机试验。
研究设计与样本
- 前瞻性研究,纳入20例对放化疗达完全缓解且无脑转移的局限期小细胞肺癌成人患者,中位年龄61岁。
- PCI方案为25 Gy/10次,海马平均剂量<8 Gy,≥90%脑组织接受90%处方剂量。
- 主要终点为PCI后6个月Hopkins Verbal Learning Test-Revised延迟回忆记忆评分,以RTOG 0212的25 Gy组为潜在疗效参考。
主要发现
- 2年总生存率为88%(95%CI 68%-100%)。
- 基线至6或12个月所有神经心理测试均无显著下降,基线智商与测试变化无显著关联。
- MRI显示无症状脑转移累积发生率为20%,无同期颅外进展。
- 2例低剂量区转移均未累及齿状回,其中1例累及保护区域,且两例均同期出现完全治疗脑区的额外转移。
- 发生2例神经系统死亡。
关键数值与推荐
- 海马平均剂量限制为<8 Gy,≥90%脑组织接受90%处方剂量。
- PCI剂量为25 Gy/10次。
- 主要终点为6个月Hopkins Verbal Learning Test-Revised延迟回忆。
临床怎么用
- 海马保护PCI可作为局限期小细胞肺癌完全缓解患者的治疗选择,但需告知保护区域失败风险。
- 治疗中应严格遵循海马平均剂量<8 Gy及脑组织剂量覆盖要求。
- 治疗后需定期MRI随访监测颅内转移,包括低剂量区。
局限性
- 样本量小(20例),非随机对照设计。
- 以RTOG 0212的25 Gy组为历史参考,非同期对照。
- 随访时间有限,长期认知影响及失败模式需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To prospectively evaluate cognitive function and intracranial failure patterns after hippocampal-sparing prophylactic cranial irradiation (PCI) for limited-stage small cell lung cancer (SCLC). METHODS AND MATERIALS: Adults with limited-stage SCLC, achieving a complete response to chemoradiotherapy and no brain metastases, were eligible. Patients received PCI 25 Gy/10 fractions, with a mean hippocampal dose limited to <8 Gy and ≥90% of the brain receiving 90% of the prescription. A diverse battery of neuropsychological testing was performed at baseline and 6 and 12 months after PCI. Brain MRI scans were performed at baseline and 6, 12, 18, and 24 months. The primary endpoint was memory measured by the Hopkins Verbal Learning Test-Revised Delayed Recall at 6 months after PCI. The 25-Gy arm of Radiation Therapy Oncology Group protocol 0212 was used as a reference of potential efficacy. Development of intracranial metastases was recorded. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. RESULTS: Eight men and 12 women with a median age of 61 years enrolled. Two-year overall survival was 88% (95% confidence interval 68%-100%). There was no significant decline in performance between baseline and 6 or 12 months for any of the tests. The association between baseline intelligence quotient and change in performance on testing was not significant. Magnetic resonance imaging revealed asymptomatic brain metastases at a cumulative rate of 20%, with no concurrent extracranial progression. Two patients developed a metastasis in the under-dosed region. Neither involved the dentate gyrus, but 1 involved the avoidance region. Both patients concurrently developed additional metastasis in fully treated brain regions. There were 2 neurologic deaths. CONCLUSIONS: This prospective study suggests a potential benefit of hippocampal sparing in limiting the neuropsychological sequelae of brain radiation, but with a risk of failures in the spared region. These data strongly support continued enrollment on ongoing cooperative group randomized trials. Clinical Trials registration number: NCT01797159.
引用
- Redmond KJ, Hales RK, Anderson-Keightly H, et al. Prospective Study of Hippocampal-Sparing Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581401. doi:10.1016/j.ijrobp.2017.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。